NasdaqGS:DNLIBiotechs
Denali Therapeutics (DNLI) Is Down 6.4% After Takeda Exits DNL593 Partnership - What's Changed
In early May 2026, Denali Therapeutics announced that partner Takeda will terminate their collaboration on DNL593 for strategic reasons unrelated to efficacy or safety, returning full development and commercialization rights to Denali.
This shift gives Denali complete control over DNL593 and its underlying TransportVehicle technology, which it expects to further highlight with planned phase I/II data by the end of 2026.
We will now examine how Denali regaining full rights to DNL593 could...